Registration Renewal and Validity Management for Medical Devices in Iran

1. Key takeaways

Public sources give two versions of the validity period of an Iranian registration: one is 4 years (an EU-funded industry briefing, 2020), the other is 5 years (prevailing industry practice, with renewal to be applied for approximately 6 months in advance). GRZAN’s assessment is that neither version appears in any current text published uniformly and officially by Iran, and companies must rely on the validity period stated on their own registration approval documents, scheduling the work on the basis of starting the renewal 6 months in advance so that a gap in coverage is avoided. A lapse does not merely pause sales — it removes the product from the market, which is why the calendar around renewal deserves the same rigor as the original registration project, and why the dates should be owned by a named person rather than by a shared mailbox, with each date in the plan tied to a concrete deliverable.

2. Legal basis

1. Validity period of registration: industry sources give two versions, 4 years and 5 years, with renewal initiated approximately 6 months in advance — neither version appears in any current text published uniformly and officially by Iran, and both are practical estimates; the validity period stated in the registration approval documents prevails. The two figures may each be correct for the products and the period they describe, which is precisely why neither can be generalised into a planning assumption for a different product or a different year.
2. Renewal documentation is usually identical to the original submission dossier, and the quality system certificate, the CFS and the test reports must be updated — this is a practical estimate. The practical consequence is that the renewal workload is closer to a fresh submission than to a formality, and the document refresh times must be planned, not discovered. Recording the update cycle of each document in the ledger keeps the renewal plan and the document plan in step with each other.
3. Law on the Administration of Medical, Pharmaceutical, Food and Beverage Affairs, FAOLEX LEX-FAOC227692, dated 1955-06-20, Article 3 (sale without approval is prohibited). This is the provision that makes a lapsed registration a market-exit event rather than an administrative inconvenience.

3. Expert insights

Insight one: the cost of a lapse is relaunching on the market, not merely suspending sales. Continuing to sell after the registration has expired constitutes the sale without approval referred to in Article 3, and the consequences are far greater than delayed deliveries. The timing of a renewal should therefore be designed around a zero-gap target, in which the new certificate takes effect before the old one expires, leaving no day on which the product is on the market without valid approval. Every intermediate date — document refresh, submission, follow-up — should be planned backwards from that single target. The zero-gap target also defines what the reminders are for: each alert should mark a date by which a concrete document must be ordered, not merely a date to think about the renewal.

Insight two: the preparation cycle for renewal documents is close to that of the original submission. The quality system certificate, the CFS and the test reports all need to be updated, and the CFS and consular legalisation themselves have processing lead times that cannot be compressed at will. Companies that assume renewal is just a formality tend to expose problems exactly at the documentation stage, when the remaining time is no longer sufficient to refresh every certificate and the only remaining option is to accept a gap. Ordering the CFS early is therefore the single scheduling decision that protects the whole timeline, because it is the document with the least controllable lead time.

Insight three: renewal is a window for renegotiating the agency terms. If the exclusivity terms of the first cooperation are approaching expiry, the renewal point is the most natural moment to adjust the commercial conditions, since both parties must engage with each other anyway to complete the filing. Combining the two reviews also saves a round of internal approvals, because the same data supports both exercises. Treating the regulatory event and the commercial review as one combined exercise avoids the situation where the commercial discussion starts only after the regulatory deadline has already forced the company’s hand.

4. Practical recommendations

1. Take the validity period stated in the approval documents as the only basis: never schedule the work using any second-hand version of the validity period, however widely the figure is quoted in industry discussions, and record where each product’s date comes from.
2. Start 6 months in advance: plan backwards from that benchmark to set the update dates for the CFS, the legalisation and the test reports, so that each document is refreshed in time and the submission is not held up by a single missing paper.
3. Maintain a validity period ledger: manage it with three columns — model, IRC and validity period — and set multiple reminders so that no single missed alert can cause a lapse, and so that the picture across the whole portfolio is visible at a glance.
4. Treat renewal as a review window for commercial terms: assess at the same time whether the agency terms need adjustment, so that regulatory and commercial cycles are aligned instead of drifting apart and colliding at the worst possible moment.

5. Verification checklist

• □ The registration validity period is based on the approval documents, with no second-hand version in use
• □ The update dates for the CFS, legalisation and test reports have been planned backwards from 6 months in advance
• □ A validity period ledger has been established with the three columns of model, IRC and validity period
• □ The renewal document list has been drawn up and owners have been designated
• □ The feasibility of using the renewal point as a review window for agency terms has been assessed

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iranian market. Our team manages adverse event reporting and recall coordination with IFDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com